Ann: Immutep to present at Ladenburg Thalmann conference, page-9

Ahjay
slide 8 - first time mention (from memory) of cost of goods in a presentation. EftIagImod:-
"Estimated favourable (low) cost of goods based on current flat dosing regimen and manufacturing process"
MInor in and of Itself but very relevant from a busIness dIfferentIal proposItIon If EftI eventually EMA/FDA approved
Marc also mentIoned (prompted by moderator) about European AIPAC phase 2b results If positIve and gain condItIonal EMA approval could In prInciple be "brIdged" to USA